Stockscreener 앱 받기
14.06
6.14%
-0.92
전일 마감가:
$14.98
열려 있는:
$14.88
하루 거래량:
1.51M
Relative Volume:
1.42
시가총액:
$1.10B
수익:
$114.04M
순이익/손실:
$-330.15M
주가수익비율:
-2.9725
EPS:
-4.73
순현금흐름:
$-274.85M
1주 성능:
-6.36%
1개월 성능:
-7.74%
6개월 성능:
+68.79%
1년 성능:
+102.01%
1일 변동 폭
$13.88
$14.96
1주일 범위
$13.79
$16.11
52주 변동 폭
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
14.06 | 1.17B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 개시 | Raymond James | Strong Buy |
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Investment Review: Is Alexanders Inc a momentum stockJuly 2025 Volume & Technical Pattern Based Signals - baoquankhu1.vn
Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook - Investing.com Canada
Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 By Investing.com - Investing.com Canada
Bond Watch: Whats Phathom Pharmaceuticals Incs historical return2025 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Breakeven On The Horizon For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - 富途牛牛
Growth Review: Does Phathom Pharmaceuticals Inc have strong fundamentalsJuly 2025 Price Swings & Reliable Price Breakout Alerts - baoquankhu1.vn
(PHAT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Phathom Pharmaceuticals: VOQUEZNA hits 1 million U.S. prescriptions milestone - Traders Union
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.6%Here's What Happened - MarketBeat
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Should Phathom’s US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? - Yahoo Finance
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Institution Moves: Can Phathom Pharmaceuticals Inc. stock hit analyst price targets2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability - Sahm
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - Улправда
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - marketscreener.com
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - Улправда
What's Going On With Phathom Pharma Stock Thursday?Phathom Pharmaceuticals (NASDAQ:PHAT) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom Pharmaceuticals (PHAT) Stock Analysis: Unveiling a 26.66% Upside Potential Despite Negative Earnings - DirectorsTalk Interviews
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals prices $130 million public offering - Investing.com
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Drug maker plans $130M stock sale to fund new gut disease research - Stock Titan
About Us - FinancialContent
Phathom Pharmaceuticals, Inc.Common Stock (NQ: PHAT - FinancialContent
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView — Track All Markets
Phathom Pharmaceuticals stock falls on planned public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals drops after announcing planned equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals announces public offering of common stock - Investing.com
Phathom Pharmaceuticals (PHAT) Projects Q4 Operating Expenses - GuruFocus
Phathom Pharmaceuticals stock falls on planned public offering - Investing.com
Phathom Pharmaceuticals files for mixed shelf offering size not disclosedSEC filing - MarketScreener
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million - marketscreener.com
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 7.7%Still a Buy? - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Phathom Pharmaceuticals Inc 주식 (PHAT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
4.73%
0.92%
자본화:
|
볼륨(24시간):